Display options
Cite
Qian W, Cai X, Zhang X, et al. Effect of Daisaikoto on Expressions of SIRT1 and NF-kappaB of Diabetic Fatty Liver Rats Induced by High-Fat Diet and Streptozotocin. Yonago Acta Med. 2016;59(2):149-58
Qian, W., Cai, X., Zhang, X., Wang, Y., Qian, Q., & Hasegawa, J. (2016). Effect of Daisaikoto on Expressions of SIRT1 and NF-kappaB of Diabetic Fatty Liver Rats Induced by High-Fat Diet and Streptozotocin. Yonago acta medica, 59(2), 149-58.
Qian, Weibin, et al. "Effect of Daisaikoto on Expressions of SIRT1 and NF-kappaB of Diabetic Fatty Liver Rats Induced by High-Fat Diet and Streptozotocin." Yonago acta medica vol. 59,2 (2016): 149-58.
Qian W, Cai X, Zhang X, Wang Y, Qian Q, Hasegawa J. Effect of Daisaikoto on Expressions of SIRT1 and NF-kappaB of Diabetic Fatty Liver Rats Induced by High-Fat Diet and Streptozotocin. Yonago Acta Med. 2016 Jun 29;59(2):149-58. eCollection 2016 Jun. PMID: 27493486; PMCID: PMC4973021.
Copy Download .nbib Format: NLM
Share it on

Yonago Acta Med. 2016 Jun 29;59(2):149-58. eCollection 2016 Jun.

Effect of Daisaikoto on Expressions of SIRT1 and NF-kappaB of Diabetic Fatty Liver Rats Induced by High-Fat Diet and Streptozotocin.

Yonago acta medica

Weibin Qian, Xinrui Cai, Xinying Zhang, Yingying Wang, Qiuhai Qian, Junichi Hasegawa

Affiliations

  1. Division of Pharmacotherapeutics, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan; †Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, Shandong, China.
  2. ‡Shandong Academy Occupational Health and Occupational Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong 250002, China.
  3. †Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, Shandong, China.
  4. §Jinan Shizhong People's Hospital, Jinan 250002, Shandong, China.
  5. Division of Pharmacotherapeutics, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan.

PMID: 27493486 PMCID: PMC4973021

Abstract

BACKGROUND: Daisaikoto (DSKT), a classical traditional Chinese herbal formula, has been used for treating digestive diseases for 1800 years in China. Therefore, in this study, we are going to investigate the effect of DSKT on diabetic fatty liver rats induced by a high-fat diet and streptozotocin (STZ), and the effects of DSKT on silent mating type information regulation 2 homolog 1 (SIRT1) and nuclear factor kappa B (NF-kappaB).

METHODS: Diabetic fatty liver rat model was selected to establish a high-fat diet and STZ. Sixty Wistar rats were divided into six groups (n = 10): control group, high-fat diet + STZ group, simvastatin treatment group, DSKT low dose, medial dose and high dose treatment groups. After 8 weeks of drug intervention, body and liver weights, blood chemistry, blood glucose and insulin were examined. The expressions of sirtuin 1 and NF-kappaB in the liver were observed by RT-PCR and immunohistochemistry, respectively.

RESULTS: A high-fat diet increased body, liver weights, and serum cholesterol concentrations. Intraperitoneal injection of STZ increased blood glucose and decreased body weights. DSKT improved them. Homeostasis model assessment-estimated insulin resistance (HOMA-IR) indices were increased in the high-fat diet groups. DSKT improved them too. In histological examinations of the liver, we observed a significant improvement after treatment. Immunostaining expression of NF-kappaB in the liver was improved by DSKT and simvastatin. The mRNA expressions of SIRT1 in the liver were increased by DSKT and simvastatin.

CONCLUSION: We have demonstrated that DSKT is capable of reversing dyslipidemia and insulin resistance induced by a high-fat diet and STZ. High dose DSKT reveals a stronger effect than simvastatin on the expressions of SIRT1 and NF-kappaB. Furthermore, DSKT has shown a strong dose-depended protective effect on diabetic fatty liver.

Keywords: daisaikoto; diabetes; fatty liver; nuclear factor kappa B; silent mating type information regulation 2 homolog 1

References

  1. Transl Res. 2007 Mar;149(3):114-25 - PubMed
  2. Indian J Endocrinol Metab. 2015 Sep-Oct;19(5):597-601 - PubMed
  3. Biochim Biophys Acta. 2015 Jul;1852(7):1550-9 - PubMed
  4. PLoS One. 2015 Nov 13;10(11):e0142808 - PubMed
  5. Gastroenterology. 2002 May;122(6):1649-57 - PubMed
  6. Zhonghua Gan Zang Bing Za Zhi. 2015 Oct;23(10):760-4 - PubMed
  7. Prev Med. 2012 May;54 Suppl:S20-8 - PubMed
  8. Eur J Pharmacol. 2011 Jul 15;662(1-3):70-7 - PubMed
  9. Am J Cardiol. 2004 Oct 1;94(7):935-8 - PubMed
  10. J Ethnopharmacol. 1998 Dec;63(3):209-18 - PubMed
  11. Clin Gastroenterol Hepatol. 2004 Mar;2(3):262-5 - PubMed
  12. Am J Cardiol. 2002 Oct 17;90(8A):62i-70i - PubMed
  13. Cell Metab. 2009 Apr;9(4):327-38 - PubMed
  14. Liver Int. 2007 Jun;27(5):708-15 - PubMed
  15. J Agric Food Chem. 2016 Feb 10;64(5):1122-9 - PubMed
  16. Physiol Rev. 2012 Jul;92(3):1479-514 - PubMed
  17. Yonago Acta Med. 2015 Jun;58(2):63-8 - PubMed
  18. J Clin Exp Hepatol. 2015 Jun;5(2):147-58 - PubMed
  19. Yonago Acta Med. 2016 Mar;59(1):67-80 - PubMed
  20. J Ethnopharmacol. 1995 Apr;46(1):49-54 - PubMed
  21. Food Chem Toxicol. 2013 Feb;52:53-60 - PubMed
  22. Yonago Acta Med. 2014 Dec;57(4):147-58 - PubMed
  23. J Cereb Blood Flow Metab. 2011 Apr;31(4):1003-19 - PubMed
  24. Cell Res. 2011 Jan;21(1):103-15 - PubMed
  25. Nutrition. 2014 Jul-Aug;30(7-8):915-9 - PubMed
  26. Mol Nutr Food Res. 2014 Jun;58(6):1212-25 - PubMed
  27. Nihon Yakurigaku Zasshi. 1989 Mar;93(3):179-86 - PubMed
  28. Prog Lipid Res. 2009 Jan;48(1):1-26 - PubMed
  29. Ann Clin Lab Sci. 2014 Fall;44(4):443-8 - PubMed
  30. Thromb Res. 2011 Aug;128(2):117-23 - PubMed
  31. Diabet Med. 2005 Sep;22(9):1129-33 - PubMed
  32. J Formos Med Assoc. 2008 Oct;107(10):816-21 - PubMed
  33. Diabetes Care. 2007 May;30(5):1212-8 - PubMed
  34. Diabetologia. 1985 Jul;28(7):412-9 - PubMed

Publication Types